RISK WATCHReuters • 52m ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
Why KRYS Stock advanced +0.97% Today — RQD Quant Desk Flash
$324.55 +0.97% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
Krystal Biotech Inc. (KRYS) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (steady margins, 17% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B • BUY
Cap $9.61B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERBUY • B
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C · Rk A-
Each axis scored 0–20
12M PRICE TARGET CONE+6.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KRYS)Realized 20D OHLCV Swing Band: ±6.5%
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why KRYS Stock advanced +0.97% Today — RQD Quant Desk Flash
Krystal Biotech Inc. (KRYS) advanced +0.97% to $324.55, trading at 71% of its 52-week range ($184.02 – $382.54). High-quality cash engine (steady margins, 17% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 71% of its 52-week range ($184.02 – $382.54) with RSI-14 at 48.2 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±6.5% around $324.55 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B (Buy) backed by 52% gross margin and $188.9M annual free cash flow.
Live KRYS Headlines & Catalysts
MARKET WIREReuters • 2h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 2h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 3h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 3h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 4h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
MARKET WIREReuters • 5h ago
Pope Leo says he hopes Oleshky truce could spur Ukraine-Russia peace efforts - ReutersPope Leo says he hopes Oleshky truce could spur Ukraine-Russia peace efforts Reuters
MARKET WIREReuters • 9h ago
Xiaomi's October EV deliveries top 50,000, hit 2026 monthly high - ReutersXiaomi's October EV deliveries top 50,000, hit 2026 monthly high Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (KRYS Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 1,540+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
KRYS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +13.10%📐 WEDGE COMPRESSION COIL
2026-11-01O $321.4H $324.6L $321.4C $324.6VOL 190.9K
RES: $365.1SUP: $310.7SMA50: $337.0SMA200: $308.7
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
KRYS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
34.6%/yr Implied 5Y Growth
vs. +33.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on KRYS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for KRYS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KRYS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KRYS)
Health Care Rank #53 of 188
⚔️ PCVX vs KRYS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (KRYS vs. PCVX, IBRX, KYMR, QGEN)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (26 Tracked Issuers)Across 188 tracked Health Care securities in the Roarable RQD universe, Krystal Biotech Inc. (KRYS) ranks #53 by composite RQD confidence (72/100, grade B) and #117 by equity capitalization ($9.61B). Within this direct 5-issuer industry benchmark cohort, QGEN leads on earnings valuation at 24.4x trailing P/E, while KRYS leads on capital efficiency and profitability with 16.5% ROIC and — gross margin. KRYS currently leads its immediate peer cohort in composite quantitative strength at 72/100 (B).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| KRYS
ACTIVE
Krystal Biotech Inc. | B | 72/100 | 46.9x | — | 16.5% | +0.97% | $9.61B | Benchmark Subject |
| PCVX Vaxcyte Inc. | D | 49/100 | — | — | -27.6% | +1.87% | $9.85B | /pcvx-vs-krys → |
| IBRX ImmunityBio Inc. | D- | 38/100 | — | 96.0% | -27.3% | -0.79% | $9.26B | /ibrx-vs-krys → |
| KYMR Kymera Therapeutics Inc. | D | 50/100 | 32.7x | — | -21.4% | +0.07% | $10.19B | /kymr-vs-krys → |
| QGEN Qiagen N.V. | B- | 71/100 | 24.4x | 62.2% | 8.0% | +0.02% | $10.37B | /qgen-vs-krys → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001711279In its most recent audited fiscal period (FY2025, filed 2025-12-31), Krystal Biotech Inc. (KRYS) reported GAAP revenue of $389.1M (+33.9% vs. FY2024 revenue of $290.5M , and +667.5% cumulative change since FY2023) , GAAP net income of $204.8M, operating cash flow of $200.9M, and free cash flow of $188.9M (+58.5% YoY). On the balance sheet, KRYS closed FY2025 with $1.33B in total assets against $51.4M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $389.1M | $204.8M | $200.9M | $188.9M | $1.33B | $51.4M |
| FY2024 (FY) | 2024-12-31 | $290.5M | $89.2M | $123.4M | $119.2M | $1.06B | $49.3M |
| FY2023 (FY) | 2023-12-31 | $50.7M | $10.9M | -$88.8M | -$91.1M | $5.28B | $1.24B |
3. KRYS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs KRYS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Krystal Biotech Inc. (NASDAQ: KRYS) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $324.55 (+0.97% 1D, market cap $9.61B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 12/20. Across 188 tracked Health Care issuers, KRYS ranks #53 in composite RQD confidence.
How does KRYS compare to PCVX and IBRX in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), KRYS carries a Roarable B (72/100 RQD), trailing P/E of 46.9x, gross margin of —, and ROIC of 16.5%. By comparison, PCVX (Vaxcyte Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC -27.6%, cap $9.85B) and IBRX (ImmunityBio Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -27.3%, cap $9.26B). Among the 5-stock peer group, QGEN leads on earnings multiple (24.4x) while KRYS leads on capital efficiency (16.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for KRYS?
Per KRYS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001711279), Krystal Biotech Inc. generated $389.1M in revenue (+33.9% YoY), $204.8M in net income, and $188.9M in free cash flow against $1.33B in total assets and $51.4M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 47x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is KRYS trading relative to its 50-day, 200-day, and 52-week technical levels?
KRYS last traded at $324.55 (+0.97% on volume of 190,894 shares), positioning the stock -3.70% below its 50-day simple moving average ($337.02) and +5.12% above its 200-day simple moving average ($308.74). Across its 52-week range of $184.02 to $382.54, KRYS sits at the 70.8% percentile with a 14-day RSI of 48.2 (NEUTRAL RANGE) and an implied next-earnings move of ±6.5% ($303.45 to $345.65).
KRYS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is KRYS stock moving today?
Why KRYS Stock advanced +0.97% Today — RQD Quant Desk Flash. High-quality cash engine (steady margins, 17% return on capital) with steady institutional support.